- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01486342
PET Imaging in Patients at Risk for Acute Lung Injury (PET-ALI)
Positron Emission Tomography With [18F]Fluorodeoxyglucose in Patients at Risk for Acute Lung Injury
Despite decades of research, the mortality in acute lung injury remains very high and treatment options are very limited. Given these facts, the best treatment modality may be in prevention of this lethal syndrome.
Historically, imaging has played a crucial role in understanding ALI. The appearance of chest radiography is one of the consensus criteria in defining ALI, and commuted tomography (CT) scans further advanced the understanding of the pathoanatomy of ALI. While valuable, these imaging modalities are nonspecific and do not incorporate functional cellular physiology.
PET imaging measures concentrations of radioisotopes in the body. By embedding in, but not altering molecules, the natural fate of these tracers can be studied with PET imaging. Advances in the understanding of ALI include blood flow distribution, as well as the response to alveolar recruitment maneuvers and prone positioning. Not all patients who are receiving mechanical ventilation develop ALI. Inflammation in the lungs is known to play a key early role in the development and progression of ALI. Secondary to inflammation, the lungs develop edema and do not exchange oxygen as well. This early inflammation is in part driven by a specific type of immune cell called the neutrophil. These cells seem to travel and become sequestered in the lung- they are "recruited" to the lung during this inflammatory stage. When there, these neutrophils release inflammatory substances which are integral in the development of ALI. Neutrophils use primarily glucose as a fuel source. The radio isotope [18F]Fluorodeoxyglucose (FDG)is a glucose analog and therefore taken up/ingested by the neutrophils as a part of their normal metabolism. Because of this fact, positron emission tomography (PET) using the radio isotope [18F]FDG is a highly sensitive marker to look at the recruitment of neutrophils to the lung, therefore quantifying the degree of pulmonary inflammation prior to the development of ALI.
The investigators seek to examine the relationship of pulmonary inflammation in patients at risk for ALI, but without clinical evidence of the syndrome. The investigators seek to enroll ten patients in a pilot trial.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University in St. Louis School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults patients (age ≥ 18) presenting to the SICU after ≥ 5 hours of mechanical ventilation in the OR or ED, without clinical evidence of ALI, and LIPS > 4 or < 4.
- Able to be positioned supine within the PET/CT scanner for ~1.25 hours
- Has legally authorized representative (LAR) available and willing to give informed consent, or is able to give informed consent prior to initiation of mechanical ventilation
- BMI < 35
Exclusion Criteria:
- Established ALI by accepted clinical criteria.
- Organ transplant recipient
- Treatment with immunosuppressive/immune-modulating medications
- Current corticosteroid treatment
- Chronic pulmonary or nonpulmonary inflammatory diseases
- Inability to safely travel out of the SICU (as established by regular safety screening criteria). Patient is placed in the supine position for a minimum of 30 minutes, and on mechanical ventilator settings that will be in place for the duration of the FDG-PET study. The patient is deemed unsafe for travel if oxygen requirement increases or any hemodynamic instability ensues (such as increasing vasopressor requirements).
- Glucose level > 150 mg/dl at time of PET scan
- Pregnancy (confirmed by qualitative urine hCG pregnancy test)
- Lactation
- Presence of implanted electronic medical device
- Enrollment in another research study of an investigational drug
- Prior research-related radiation exposure within the past year such that participation in this study would result in exposures that exceed the limits as defined by the FDA RDRC regulations (21 CFR 361.1)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
|
PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging. A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The influx constant (Ki) of FDG uptake
Time Frame: 3 days
|
The influx constant describes the rate of FDG uptake and represents pulmonary inflammation
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlation of the influx constant (Ki) with lung injury prediction score
Time Frame: 3 days
|
3 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Brian Fuller, MD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201105122
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lung Injury
-
Yangzhou UniversityCompleted
-
Damanhour UniversityAlexandria UniversityCompletedAcute Lung Injury, Transfusion RelatedEgypt
-
Taipei Medical University WanFang HospitalUnknown
-
Virginia Commonwealth UniversityCompletedCOVID-19 | Kidney Injury | Lung Injury, AcuteUnited States
-
Kocaeli UniversityCompletedVentilator-Induced Lung Injury | Ventilator Adverse Event | Lung Injury, AcuteTurkey
-
All India Institute of Medical Sciences, RishikeshUnknownLung Injury, Acute
-
GlaxoSmithKlineCompleted
-
Vanderbilt UniversityTerminated
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Completed
Clinical Trials on PET-CT scan
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Radboud University Medical CenterUnknownCarcinoma, Non Small Cell LungNetherlands
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonRecruiting
-
Colchester General HospitalAnglia Ruskin UniversityUnknownRectal NeoplasmsUnited Kingdom
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedLymphoma | Breast Cancer | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung CancerCanada
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedNon-Hodgkin's Lymphoma | Lung CancerUnited States
-
GE HealthcareLaboratory Corporation of AmericaNot yet recruiting
-
Radboud University Medical CenterABX advanced biochemical compounds GmbH; Radboud Translational MedicineRecruitingProstate Cancer RecurrentNetherlands
-
University of ArizonaBlue Earth Diagnostics; Banner University Medical CenterCompletedProstate AdenocarcinomaUnited States